TEVA-ZOLMITRIPTAN TABLET
Nazione: Canada
Lingua: inglese
Fonte: Health Canada
Scheda tecnica
(SPC)
08-08-2014
Alcuni documenti per questo prodotto non sono attualmente disponibili, puoi inviare una richiesta al nostro servizio clienti e ti informeremo non appena saremo in grado di ottenerli.
Invia richiesta.
Invia richiesta.
Principio attivo:
ZOLMITRIPTAN
Commercializzato da:
TEVA CANADA LIMITED
Codice ATC:
N02CC03
INN (Nome Internazionale):
ZOLMITRIPTAN
Dosaggio:
1.0MG
Forma farmaceutica:
TABLET
Composizione:
ZOLMITRIPTAN 1.0MG
Via di somministrazione:
ORAL
Confezione:
3/6/50
Tipo di ricetta:
Prescription
Area terapeutica:
SELECTIVE SEROTONIN AGONISTS
Dettagli prodotto:
Active ingredient group (AIG) number: 0134381003; AHFS:
Stato dell'autorizzazione:
CANCELLED PRE MARKET
Data dell'autorizzazione:
2015-10-16
Scheda tecnica
PRODUCT MONOGRAPH
PR
TEVA-ZOLMITRIPTAN
(zolmitriptan) tablets
1 mg and 2.5 mg
PR
TEVA-ZOLMITRIPTAN OD
(zolmitriptan) orally disintegrating tablets
1 mg and 2.5 mg
Professed Standard
Migraine Therapy
5-HT
1
Receptor Agonist
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No: 176520
Date of Revision:
July 31, 2014
2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
........................................................................................................
1
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
18
DOSAGE AND ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
.......................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 24
PART II:
Leggi il documento completo
